文献速递胸部肿瘤

立体定向消融放疗(SABR)用于治疗大于5厘米的非小细胞肺癌

Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5 cm.
PubMed 文献 · J Thorac Oncol · 2017-03-07

本中心回顾性分析63例原发或复发、直径大于5厘米的非小细胞肺癌患者,接受5次或8次SABR,中位随访54.7个月,中位生存28.3个月,2年局部控制率95.8%;3级及以上毒性30%,可能或很可能治疗相关死亡19%;合并间质性肺病患者为极高危人群。

要点

  • 肿瘤中位直径5.8厘米(范围5.1-10.4),81%为T2N0、18%为T3N0。
  • 2年局部、区域、远处控制率分别为95.8%、93.7%、83.6%。
  • 3级及以上毒性30%,放射性肺炎最常见(19%);合并间质性肺病患者中5例(63%)发生致命毒性。

核心结论

  • 大于5厘米的肺部肿瘤行SABR可获得高局部控制率和可接受的生存结局,患者合并症明显;合并间质性肺病者应被视为SABR的极高危人群。

研究设计与样本

  • 本中心分析63例连续的原发或复发、直径大于5厘米的非小细胞肺癌患者,接受5次或8次SABR,排除既往接受胸部放疗者。

主要发现

  • 中位肿瘤直径5.8厘米(范围5.1-10.4),81%为T2N0、18%为T3N0,中位Charlson合并症指数2(范围0-6)。
  • 中位随访54.7个月,中位生存28.3个月,2年无病生存率82.1%。
  • 2年局部、区域、远处控制率分别为95.8%、93.7%、83.6%,野外远处复发(一个或多个部位)是最常见失败模式(10%)。
  • 3级及以上毒性见于30%患者,放射性肺炎最常见(19%);很可能(n=4)或可能(n=8)治疗相关死亡共19%。
  • 8例(13%)存在间质性肺病,其中5例(63%)发生致命毒性。

临床怎么用

  • 作者认为合并间质性肺病的患者应被视为SABR的极高危人群。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Stereotactic ablative radiotherapy (SABR) is currently not the guideline-recommended treatment for lung tumors measuring more than 5 cm. However, improvements in radiotherapy techniques have led to increasing use of SABR for larger tumors. METHODS: We analyzed the clinical outcomes in patients with a primary or recurrent NSCLC measuring more than 5 cm and treated with five or eight fractions of SABR at our center. Patients who had prior thoracic radiotherapy were excluded. RESULTS: A total of 63 consecutive patients with a median tumor diameter of 5.8 cm (range 5.1-10.4) were identified; 81% had T2N0 disease and 18% had T3N0 disease. The median Charlson comorbidity index was 2 (range 0-6). After a median follow-up of 54.7 months, median survival was 28.3 months. Disease-free survival at 2 years was 82.1%, and the local, regional, and distant control rates at 2 years were 95.8%, 93.7%, and 83.6%, respectively. An out-of-field distant recurrence at one or more sites was the most common pattern of failure (10%). Grade 3 or higher toxicity was recorded in 30% of patients, with radiation pneumonitis being the most common toxicity (19%). A likely (n = 4) or possible (n = 8) treatment-related death was scored in 19% of patients. There was preexisting interstitial lung disease in eight patients (13%), with fatal toxicity developing in five of them (63%). CONCLUSIONS: Lung SABR in tumors larger than 5 cm resulted in high local control rates and acceptable survival outcomes in a patient population with appreciable comorbidity. Patients with interstitial lung disease should be considered a very high-risk population for SABR.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Tekatli H, van 't Hof S, Nossent EJ, et al. Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5 cm. J Thorac Oncol. 2017. PMID: 28286243. doi:10.1016/j.jtho.2017.02.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。